Tesamorelin dosage & side effects
The historical trial regimen came with a diagnosis, a formulation and safety monitoring. The amount alone leaves most of that context out.
Tesamorelin dosage per day: study regimens
The pivotal 26-week trial studied 2 mg subcutaneously once daily in adults with HIV and abdominal fat accumulation. The 52-week program also used 2 mg daily, as did the 6-month liver-fat trial. These are descriptions of what those studies gave their subjects.
The human exposure-response analysis covered 1–2 mg subcutaneous daily treatment. Other study amounts answered other research questions. The pivotal abdominal-fat result is attached to the tested regimen and population.
I resist reducing the paper to its dose line. The same number loses its meaning when detached from the formulation, the eligibility criteria and the measurements used to judge benefit or harm. None of these historical amounts establishes an appropriate amount for a reader.
Tesamorelin injections
Human trials used a tesamorelin injection beneath the abdominal skin. That is the subcutaneous route described in the large abdominal-fat trial and the liver-fat experiment. The approved medicine uses a subcutaneous route too.
The prescription preparation begins as powder, and its own label governs mixing, refrigerated storage and the allowed period after reconstitution. Those formulation-specific instructions cannot be reconstructed from a research dose. Laboratory material also lacks the approved product’s purity and potency oversight.
A search for “tesamorelin dosage for belly fat” often leaves out the key clinical context: the pivotal studies concerned HIV-associated abdominal fat accumulation. Their regimen supplies no established general-population fat-loss dose. Prescription decisions require a licensed provider’s assessment; not everyone qualifies.
Tesamorelin side effects
The trial record describes soreness or redness at the injection site and growth-hormone-related effects such as fluid retention. Fluid retention means extra water held in the body, sometimes producing swelling. The longer follow-up considered safety alongside continued visceral-fat reduction.
I give the adverse-effect column equal billing with the scan result. The sources here do not supply a simple frequency for each symptom, so I cannot offer a dependable “one person in…” figure for an individual side effect. A pooled review’s favourable safety description also cannot settle every risk in longer use.
The NIH safety overview describes the prescription drug and its growth-factor context. Active malignancy is a labelled contraindication. Tesamorelin raises IGF-1, which supports cell growth; the absence of an excess malignancy signal during 52 weeks of trials leaves long-term cancer safety unresolved.
Glucose and IGF-1
In the 2-week study of 13 healthy men, neither the fasting-glucose change nor the change in insulin-stimulated glucose uptake was statistically significant. The reported P values were 0.93 and 0.61 respectively. In the 52-week HIV program, changes in glucose parameters were not clinically significant.
Those observations are reassuring within their duration and populations. Growth-hormone stimulation can still perturb glucose, and the existing clinical guidance calls for glucose monitoring in people with prediabetes or dysglycemia. The pivotal trial’s 81.0% IGF-1 increase describes a study result, with no personal target implied.
I worry when a favourable average is asked to settle an individual safety question. The mechanism explains why the growth-factor and glucose questions arise in the first place.
Liver injury and sports rules
The LiverTox monograph assigns tesamorelin a likelihood score of E, meaning an unlikely cause of clinically apparent liver injury. It notes no attributable liver-injury cases and no new serum-enzyme elevations in trials. That judgment concerns liver injury specifically.
Tesamorelin is prohibited in sport under WADA’s S2 category, both in and out of competition. Its prescription status and the short plasma half-life do not provide permission under sports rules. I would separate that eligibility question from whether a trial reported a particular side effect.